- ►diabetesjournals.org I Bachmakov, H Glaeser, MF Fromm, J König - Diabetes, 2008 - Am Diabetes Assoc OBJECTIVE—The uptake of drugs into hepatocytes is a key determinant for
hepatic metabolism, intrahepatic action, their subsequent systemic plasma
concentrations, and extrahepatic actions. In vitro and in vivo studies ... Cited by 10 - Related articles - All 4 versions
O Zolk, TF Solbach, J König, MF Fromm - Naunyn-Schmiedeberg's Archives of Pharmacology, 2009 - Springer Abstract The organic cation transporter 2 (OCT2) provides an important pathway
for the uptake of cationic compounds in the kidney, which is the essential step
in their elimination from the organism. Although many drugs have been ... Cited by 3 - Related articles - All 2 versions
A Kalliokoski, JT Backman, KJ Kurkinen, PJ … - Clinical Pharmacology & Therapeutics, 2008 - nature.com In a randomized crossover study, 24 SLCO1B1-genotyped healthy volunteers were
given daily doses of 1,200 mg gemfibrozil, 40 mg atorvastatin, or placebo,
followed by 0.25 mg of repaglinide on day 3. The mean increase in the ... Cited by 6 - Related articles - All 4 versions
O Zolk, TF Solbach, J Konig, MF Fromm - Drug Metabolism and Disposition, 2009 - ASPET The organic cation transporter 2 (OCT2, SLC22A2) plays an important role for
renal drug elimination. Recent clinical studies indicate an impact of the
frequent nonsynonymous c.808G>T (p.270Ala>Ser) polymorphism on renal ... Cited by 1 - Related articles - All 3 versions
A Kalliokoski, M Neuvonen, PJ Neuvonen, M … - The Journal of Clinical Pharmacology, 2008 - jcp.sagepub.com Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 0.5-mg
dose of repaglinide and 60-mg dose of nateglinide with a washout period of 1
week. Participants with SLCO1B1 c.521CC genotype (n = 4) had a 59% (P = ... Cited by 14 - Related articles - BL Direct - All 8 versions
A Kalliokoski, M Neuvonen, PJ Neuvonen, M … - British Journal of Clinical Pharmacology, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 2 - Related articles - All 4 versions
ZJ Wang, OQP Yin, B Tomlinson, MSS Chow - Pharmacogenetics and Genomics, 2008 - journals.lww.com Purpose Genetic polymorphisms of organic cation transporter 2 (OCT2) have been
recently described, but their genotype–phenotype relationship in humans is
unknown. We performed this study to (i) characterize genetic variations of ... Cited by 11 - Related articles - All 4 versions
A Kalliokoski, JT Backman, PJ Neuvonen, M … - Pharmacogenetics and Genomics, 2008 - journals.lww.com Cited Here...: The AUC 0-∞ and C max of repaglinide were 32% (P=0.007) and 24%
lower (P=0.056) in the individuals with the SLCO1B1*1B/*1B genotype than in
those with the SLCO1B1*1A/*1A genotype. The mean blood glucose ... Cited by 5 - Related articles - All 3 versions
A Tornio, M Niemi, M Neuvonen, J Laitila, A … - Clinical Pharmacology & Therapeutics, 2008 - nature.com Repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and 3A4. Gemfibrozil has
the effect of increasing the area under the concentration–time curve (AUC) of
repaglinide eightfold. We studied the effect of dosing interval on the ... Cited by 4 - Related articles - All 4 versions
